Resolve Therapeutics to Present Platform and Clinical Progress on Cell-Free Nucleic Acid Targeting

Resolve Therapeutics to Present Platform and Clinical Progress on Cell-Free Nucleic Acid Targeting

By, Admin 18 November 2025

Resolve Therapeutics, a mid-stage biopharmaceutical company developing non-immunosuppressive therapies for inflammatory diseases, announced it will present updates on its platform and clinical programs in an upcoming talk titled “Cell-free Nucleic Acids as Drug Targets in Autoimmunity and Acute Brain Injury.”

The presentation, to be delivered by Dr. James Posada, chief executive officer of Resolve Therapeutics, is scheduled for December 4, 2025, in Hong Kong. Dr. Posada said the forum offers an opportunity to engage with leading scientists and clinicians working in the emerging field of cell-free nucleic acids. He noted that recent scientific advances continue to highlight the role of pathogenic nucleic acids in driving inflammation across several diseases with significant unmet need.

RSLV-132: Lead Clinical Candidate

RSLV-132 is a fully human, non-immunosuppressive biologic designed to break down extracellular pathogenic cell-free RNA (cfRNA).
Key features include:

  • Fusion of catalytically active human RNase with an engineered IgG1 Fc domain
  • A three-week serum half-life
  • A safety profile supported by clinical studies

Unlike conventional immunosuppressive therapies that broadly inhibit immune activity, RSLV-132 aims to remove cfRNA, the upstream inflammatory trigger. Clinical activity has been observed in systemic lupus erythematosus (SLE) and Sjögren’s disease, and a phase 2 confirmatory trial is underway in Sjögren’s patients with moderate to severe symptoms.

RSLV-145: Dual-Action Preclinical Candidate

RSLV-145 is a fully human molecule combining active DNase and RNase enzymes fused to an optimized IgG1 Fc region. It is engineered to eliminate pathogenic extracellular nucleic acids implicated in both chronic and acute inflammatory conditions.

Ongoing preclinical development focuses on:

  • Subarachnoid hemorrhage, where reducing cfRNA may limit brain injury
  • Ischemic stroke, where DNase activity may help counteract neutrophil extracellular traps (NETs) that interfere with standard tPA therapy

About Resolve Therapeutics

Resolve Therapeutics develops therapies targeting cell-free nucleic acids in disease. The company’s pipeline, including RSLV-132 and RSLV-145, spans multiple acute and chronic inflammatory conditions where cfRNA, cfDNA, and NETs contribute to disease pathology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!